The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day.

0657 GMT - E.ON's first-half results contain no surprises, Deutsche Bank analysts James Brand and Olly Jeffery write. The solid results set the German energy company up strongly to meet, or even exceed, its full-year guidance. Shares closed Tuesday at 19.02 euros. (adam.whittaker@wsj.com)

0631 GMT - A weaker rupiah is likely to outweigh the benefits from lower cocoa prices for Delfi, says DBS Group Research's Zheng Feng Chee in a note. The analyst had initially expected the chocolate confectioner's 2H earnings to be an inflection point driven by cocoa cost savings. DBS cuts its 2026 and 2027 earnings forecast for Delfi by 2% and 8%, respectively, to reflect a stronger-than-expected dollar headwind. DBS maintains a hold rating on the Singapore-listed stock and target price of 1.00 Singapore dollars. Shares are 2.9% lower at S$0.84.(amanda.lee@wsj.com)

0629 GMT - Ocado's volatility remains persistent, but its execution is improving, J.P. Morgan analysts say in a note. The U.K. grocery-technology company's share price continues to react to incremental deal announcements and the expected delivery of positive underlying cash flow by the end of the year, they say. A recent contract for a large customer fulfilment center, alongside a more constructive tone from the CEO in an investor call, reinforces the potential for further wins, the analysts write. (aimee.look@wsj.com)

0605 GMT - The European consumer-goods sector had a better-than-expected earnings season in the second quarter, with robust volume-driven growth and stronger performance in emerging markets, analysts at JP Morgan say in a note. For many consumer-staples companies, guidance was reiterated and in some cases, raised, they add. Unilever, Danone, and some beer and ingredients companies are top picks for investors, the analysts say. However, premium-valuation stocks such as Lindt and Haleon show some top line softness, they add. (aimee.look@wsj.com)

0603 GMT - Henkel's first-half results demonstrated strong volume trends, Berenberg analysts say in a note. There were robust volumes in adhesive technologies, with a tailwind from forward buying, they say. Underlying growth was also supported by the electronics and industrial business, with management noting a particular stabilization of its automotive business in the second quarter. (aimee.look@wsj.com)

0602 GMT - Novo Nordisk will face hurdles in 2H as rival Eli Lilly steps up competition in the obesity-pill market, Berenberg analysts say in a research note. U.S. approval for Lilly's rival Foundayo pill in diabetes seems imminent, which should heat up competition in 2H, the analysts say. Berenberg cuts its recommendation on Novo Nordisk to hold from buy, trimming its target price to 305 Danish kroner from 325 kroner. Shares in the Danish drugmaker already reflect higher expectations for its Wegovy weight-loss pill, the analysts say. Investors will likely want confirmation that Novo Nordisk can retain its leadership in obesity oral medicines while expanding in the injection market going forward, they add. Novo Nordisk shares closed at 307.20 kroner Tuesday. They are down 5.55% since the start of 2026.(adria.calatayud@wsj.com)

0559 GMT - E.ON's is well on its way to achieving its full-year adjusted net income target, Jefferies analysts Ahmed Farman and Arturo Murua write. The German energy company has achieved around 68% of the mid-point of guidance, which is 2.8 billion euros, they note. In the past 3 years, the company has on average earned around 1 billion euros extra over the second half of they year, they say. This means the upper end of its guidance of 2.9 billion euros looks well within reach, they say. Shares closed Tuesday at 19.02 euros.(adam.whittaker@wsj.com)

0551 GMT - Clariant's litigation risk has eased and the Swiss chemical company's earnings growth next year should allow share outperformance, Berenberg analyst Sebastian Bray writes in a research note. According to Bray, Clariant has two advantages over the diversified chemicals sector. First, the threat related to cartel litigation in Europe has become manageable after a recent Dutch court decision. Second is a recovery in catalysis alongside abating forex headwinds that should let Clariant generate good earnings growth in 2027, he says. Berenberg upgrades Clariant to buy from hold and raises the target price to 12 Swiss francs from 7.80 francs. Shares closed Tuesday at 10.04 francs.